IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis

Journal of Clinical Investigation

Volumn 115, Issue 10, 2005, Pages 2731-2741

  Kaplin, Adam I ^a   Deshpande, Deepa M ^a   Scott, Erick ^a   Krishnan, Chitra ^a   Carmen, Jessica S ^a   Shats, Irina ^a   Martinez, Tara ^a   Drummond, Jennifer ^a   Dike, Sonny ^a   Pletnikov, Mikhail ^a   Keswani, Sanjay C ^a   Moran, Timothy H ^a   Pardo, Carlos A ^a,b   Calabresi, Peter A ^a   Kerr, Douglas A ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE; STAT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BRAIN VENTRICLE; CELL DAMAGE; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MYELITIS; NERVE FIBER DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD INJURY; TISSUE CULTURE; WESTERN BLOTTING;

ADULT; ANIMALS; AXONS; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MICE; MYELITIS, TRANSVERSE; NITRIC OXIDE SYNTHASE TYPE II; ORGAN CULTURE TECHNIQUES; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-TYROSINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SPINAL CORD; SPINAL CORD INJURIES; STAT TRANSCRIPTION FACTORS;

EID: 26444619864     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI25141     Document Type: Article

References (45)

1. Krishnan, C., Kaplin, A.I., Deshpande, D.M., Pardo, C.A., and Kerr, D.A. 2004. Transverse myelitis: pathogenesis, diagnosis and treatment. Front. Biosci. 9:1483-1499.
2. Gadient, R.A., and Otten, U.H. 1997. Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials. Prog. Neurobiol. 52:379-390.
3. Ransohoff, R.M., Howe, C.L., and Rodriguez, M. 2002. Growth factor treatment of demyelinating disease: at last, a leap into the light. Trends Immunol. 23:512-516.
4. Gruol, D.L., and Nelson, T.E. 1997. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol. Neurobiol 15:307-339.
5. Wilson, C.J., Finch, C.E., and Cohen, H.J. 2002. Cytokines and cognition-the case for a head-to-toe inflammatory paradigm. J. Am. Geriatr. Soc. 50:2041-2056.
6. Campbell, I.L., et al. 1993. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. U. S. A. 90:10061-10065.
7. Okuda, Y., et al. 1998. IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol. 10:703-708.
8. Gijbels, K., Brocke, S., Abrams, J.S., and Steinman, L. 1995. Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation. Mol Med. 1:795-805.
9. Tuna, M., et al. 2001. Effect of anti-rat interleukin-6 antibody after spinal cord injury in the rat: inducible nitric oxide synthase expression, sodium- and potassium-activated, magnesium-dependent adenosine-5′- triphosphatase and superoxide dismutase activation, and ultrastructural changes. J. Neurosurg. 95:64-73.
10. Yu, X., Kennedy, R.H., and Liu, S.J. 2003. JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes. J. Biol Chem. 278:16304-16309.
11. Van Wagoner, N.J., and Benveniste, E.N. 1999. Interleukin-6 expression and regulation in astrocytes. J. Neuroimmunol. 100:124-139.
12. Liberatore, G.T., et al. 1999. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5:1403-1409.
13. Abramson, S.B., Amin, A.R., Clancy, R.M., and Attur, M. 2001. The role of nitric oxide in tissue destruction. Best Pract. Res. Clin. Rheumatol. 15:831-845.
14. Dawson, V.L., Brahmbhatt, H.P., Mong, J.A., and Dawson, T.M. 1994. Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology. 33:1425-1430.
15. Lieb, K., Engels, S., and Fiebich, B.L. 2003. Inhibition of LPS-induced iNOS and NO synthesis in primary rat microglial cells. Neurochem. Int. 42:131-137.
16. Calabrese, V., et al. 2002. Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. J. Neurosci. Res. 70:580-587.
17. Shin, T., Kim, S., Moon, C., Wie, M., and Kim, H. 2000. Aminoguanidine-induced amelioration of autoimmune encephalomyelitis is mediated by reduced expression of inducible nitric oxide synthase in the spinal cord. Immunol. Invest. 29:233-241.
18. Isaksson, J., Farooque, M., and Olsson, Y. 2005. Improved functional outcome after spinal cord injury in iNOS-deficient mice. Spinal Cord. 43:167-170.
19. Blantz, R.C., and Munger, K. 2002. Role of nitric oxide in inflammatory conditions. Nephron. 90:373-378.
20. Scott, G.S., Szabo, C., and Hooper, D.C. 2004. Poly(ADP-ribose) polymerase activity contributes to peroxynitrite-induced spinal cord neuronal cell death in vitro. J. Neurotrauma. 21:1255-1263.
21. Burkle, A. 2001. Physiology and pathophysiology of poly(ADP-ribosyl) ation. Bioessays. 23:795-806.
22. Ha, H.C., and Snyder, S.H. 2000. Poly(ADP-ribose) polymerase-1 in the nervous system. Neurobiol. Dis. 7:225-239.
23. Genovese, T., et al. 2005. Inhibitors of poly (ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma. J. Pharmacol. Exp. Ther. 312:449-457.
24. Irani, D.N., and Kerr, D.A. 2000. 14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis [letter]. Lancet. 355:901.
25. Radi, R. 2004. Nitric oxide, oxidants, and protein tyrosine nitration. Proc. Natl. Acad. Sci. U. S. A. 101:4003-4008.
26. Hill, K.E., Zollinger, L.V., Watt, H.E., Carlson, N.G., and Rose, J.W. 2004. Inducible nitric oxide synthase in chronic active multiple sclerosis plaques: distribution, cellular expression and association with myelin damage. J. Neuroimmunol. 151:171-179.
27. Michalopoulou, M., et al. 2004. Soluble interleukin-6 receptor (sIL-6R) in cerebrospinal fluid of patients with inflammatory and non inflammatory neurological diseases. Immunol. Lett. 94:183-189.
28. Transverse Myelitis Consortium Working Group. 2002. Proposed diagnostic criteria and nosology of acute transverse myelitis [review]. Neurology. 59:499-505.
29. Ravin, P., and Hedley-Whyte, E.T. 2002. Case records of the Massachusetts Genera Hospital. Weekly clinicopathological exercises. Case 34-2002. A 55-year-old man with cognitive and sensorimotor findings and intracranial lesions. N. Engl. J. Med. 347:1433-1440.
30. Miljkovic, D.J., et al. 2002. Nitric oxide metabolites and interleukin-6 in cerebrospinal fluid from multiple sclerosis patients. Eur. J. Neurol. 9:413-418.
31. Mycko, M.P., Papoian, R., Boschert, U., Raine, C.S., and Selmaj, K-W. 2003. cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain. 126:1048-1057.
32. Lock, C., et al. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelins. Nat. Med. 8:500-508.
33. Ishihara, K., and Hirano, T. 2002. Molecular basis of the cell specificity of cytokine action. Biochim. Biophys. Acta. 1592:281-296.
34. Rodriguez, M., Pavelko, K.D., McKinney, C.W., and Leibowitz, J.L. 1994. Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J. Immunol. 153:3811-3821.
35. Zhang, P., Chebath, J., Lonai, P., and Revel, M. 2004. Enhancement of oligodendrocyte differentiation from marine embryonic stem cells by an activator of gp130 signaling. Stem Cells. 22:344-354.
36. Kaplin, A.I., Krishnan, C., Deshpande, D.M., Pardo, C.A., and Kerr, D.A. 2005. Diagnosis and management of acute myelopathies. Neurologist. 11:2-18.
37. Lynch, J.R., et al. 2003. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J. Biol. Chem. 278:48529-48533.
38. Takeda, K., et al. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity. 10:39-49.
39. Stagi, M., et al. 2005. Breakdown of axonal synaptic vesicle precursor transport by microglial nitric oxide. J. Neurosci. 25:352-362.
40. Kiefmann, R., et al. 2004. Role of PARP on iNOS pathway during endotoxin-induced acute lung injury. Intensive Care Med. 30:1421-1431.
41. Ha, H.C. 2004. Defective transcription factor activation for proinflammatory gene expression in poly(ADP-ribose) polymerase 1-deficient glia. Proc. Natl. Acad. Sci. U. S. A. 101:5087-5092.
42. Regan, R.F. 1996. The vulnerability of spinal cord neurons to excitotoxic injury: comparison with cortical neurons. Neurosci. Lett. 213:9-12.
43. Binder, G.K., and Griffin, D.E. 2001. Interferon-gamma-mediated site-specific clearance of alpha-virus from CNS neurons. Science. 293:303-306.
44. Babas, T., et al. 2003. Role of microglial cells in selective replication of simian immunodeficiency virus genotypes in the brain. J. Virol. 77:208-216.
45. Rothstein, J.D., Jin, L., Dykes-Hoberg, M., and Kuncl, R.W. 1993. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 90:6591-6595.